Table 3.
Effect of 40 months of intervention of Omega-3 fatty acids on decline in creatinine–cystatin C-based kidney function in 2344 patients of the Alpha Omega Trial with or without CKD at baseline according to treatment group
| Treatment Groups | Creatinine–Cystatin C-based eGFR (ml/min per 1.73 m2)a | |||
|---|---|---|---|---|
| Pretreatment (Mean±SD) | Post-Treatment (Mean±SD) | Decline (Mean±SD) | Treatment Effect Mean (95% CI)b | |
| ≥60 ml/min per 1.73 m2 | ||||
| Placebo (n=500) | 85.0±13.1 | 77.4±16.5 | −7.6±12.5 | |
| ALA (n=503) | 85.1±14.1 | 78.0±17.0 | −7.1±12.8 | 0.6 (−1.0 to 2.1) |
| EPA-DHA (n=467) | 84.9±12.9 | 78.5±15.8 | −6.4±12.6 | 1.3 (−0.3 to 2.9) |
| EPA-DHA plus ALA (n=468) | 84.2±12.7 | 77.2±15.2 | −7.1±12.7 | 0.6 (−1.0 to 2.2) |
| <60 ml/min per 1.73 m2 | ||||
| Placebo (n=93) | 48.2±10.1 | 45.4±15.4 | −2.8±12.3 | |
| ALA (n=98) | 47.7±9.4 | 45.7±14.9 | −2.0±11.7 | 0.9 (−2.6 to 4.3) |
| EPA-DHA (n=109) | 49.4±8.6 | 51.5±16.9 | 2.1±14.8 | 4.9 (1.1 to 8.7) |
| EPA-DHA plus ALA (n=106) | 48.6±10.2 | 47.2±17.9 | −1.4±13.1 | 1.4 (−2.2 to 5.0) |
a
On the basis of the Chronic Kidney Disease Epidemiology Collaboration equation of 2012 (15). CKD was defined as eGFR<60 ml/min per 1.73 m2.
b
Decline in intervention group minus decline in placebo group with 95% CI. The P value for interaction with regard to change of eGFR between CKD at baseline (yes or no) and ALA versus placebo was 0.67; for EPA-DHA versus placebo, P for interaction was 0.07, and for EPA-DHA plus ALA versus placebo, P value for interaction was 0.89.